Loading clinical trials...
Loading clinical trials...
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Conditions
Interventions
Encorafenib
Binimetinib
+2 more
Locations
3
United States
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Start Date
July 29, 2019
Primary Completion Date
April 30, 2022
Completion Date
October 1, 2023
Last Updated
October 31, 2024
NCT03340506
NCT05278208
NCT05868629
NCT05212272
NCT05839379
NCT04655404
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions